NN Investment Partners Holdings N.V. purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the second quarter, Holdings Channel reports. The institutional investor purchased 208,162 shares of the company’s stock, valued at approximately $9,576,000. NN Investment Partners Holdings N.V. owned 0.24% of Neurocrine Biosciences as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in the company. Russell Investments Group Ltd. acquired a new position in Neurocrine Biosciences during the fourth quarter valued at $1,025,000. Dimensional Fund Advisors LP boosted its position in Neurocrine Biosciences by 2.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 165,953 shares of the company’s stock valued at $6,422,000 after buying an additional 4,428 shares in the last quarter. Putnam Investments LLC boosted its position in Neurocrine Biosciences by 8.8% in the fourth quarter. Putnam Investments LLC now owns 27,348 shares of the company’s stock valued at $1,058,000 after buying an additional 2,222 shares in the last quarter. Norges Bank acquired a new position in Neurocrine Biosciences during the fourth quarter valued at $34,777,000. Finally, Teachers Advisors LLC boosted its position in Neurocrine Biosciences by 6.3% in the fourth quarter. Teachers Advisors LLC now owns 78,287 shares of the company’s stock valued at $3,030,000 after buying an additional 4,668 shares in the last quarter. Institutional investors and hedge funds own 95.67% of the company’s stock.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) opened at 48.19 on Friday. Neurocrine Biosciences, Inc. has a 52 week low of $37.35 and a 52 week high of $55.38. The company’s market capitalization is $4.24 billion. The firm has a 50-day moving average price of $47.45 and a 200-day moving average price of $45.18.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Tuesday, May 9th. The company reported ($0.90) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by $0.23. During the same quarter last year, the firm posted ($0.22) earnings per share. Analysts anticipate that Neurocrine Biosciences, Inc. will post ($2.48) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/208162-shares-in-neurocrine-biosciences-inc-nasdaqnbix-acquired-by-nn-investment-partners-holdings-n-v/1440054.html.

NBIX has been the topic of several research analyst reports. Bank of America Corporation initiated coverage on Neurocrine Biosciences in a research report on Friday, May 5th. They issued a “buy” rating and a $70.00 price objective on the stock. Oppenheimer Holdings, Inc. set a $60.00 price objective on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Saturday, April 8th. BidaskClub raised Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Jefferies Group LLC boosted their price objective on Neurocrine Biosciences from $59.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, April 12th. Finally, Leerink Swann cut their price objective on Neurocrine Biosciences from $68.00 to $66.00 and set an “outperform” rating on the stock in a research report on Thursday, May 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating and sixteen have given a buy rating to the company’s stock. Neurocrine Biosciences has a consensus rating of “Buy” and an average price target of $67.69.

In other news, insider Dimitri E. Grigoriadis sold 10,000 shares of the business’s stock in a transaction dated Tuesday, May 2nd. The stock was sold at an average price of $55.00, for a total value of $550,000.00. Following the transaction, the insider now directly owns 117,691 shares in the company, valued at $6,473,005. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin Charles Gorman sold 21,739 shares of the business’s stock in a transaction dated Tuesday, May 2nd. The shares were sold at an average price of $53.23, for a total value of $1,157,166.97. Following the completion of the transaction, the chief executive officer now owns 354,346 shares in the company, valued at $18,861,837.58. The disclosure for this sale can be found here. Insiders sold 71,699 shares of company stock worth $3,855,122 over the last 90 days. Company insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.